Our finding on the effects of LG100754 on T cells is consistent with that of a previous study reporting that the LG100268, an RXR–PPARγ heterodimer agonist, has favorably modulated the immune microenvironment in preclinical breast cancer models [74,75]. Here, PPARG is linked to breast carcinoma.